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Abstract
The biologic effects and mechanisms by which bone morphogenetic proteins (BMPs) function in breast cancer cells are not
well defined. A member of this family of growth and differentiation factors, BMP-2, inhibited both basal and estradiol-
induced growth of MCF-7 breast tumor cells in culture. Flow cytometric analysis showed that in the presence of BMP-2, 62%
and 45% of estradiol-stimulated MCF-7 cells progressed to S-phase at 24 h and 48 h, respectively. Estradiol mediates growth
of human breast cancer cells by stimulating cyclins and cyclin-dependent kinases (CDKs). BMP-2 significantly increased the
level of the cyclin kinase inhibitor, p21, which in turn associated with and inactivated cyclin D1. BMP-2 inhibited estradiol-
induced cyclin D1-associated kinase activity. Also estradiol-induced CDK2 activity was inhibited by BMP-2. This inhibition
of CDK activity resulted in hypophosphorylation of retinoblastoma protein thus keeping it in its active form. These data
provide the first evidence by which BMP-2 inhibits estradiol-induced proliferation of human breast cancer cells. ß 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
17-L-Estradiol (estradiol) acts as a potent mitogen
for breast epithelial cells and thus causes increased
cell growth, both in vivo and in vitro. In estradiol-
responsive human breast cancer cells like MCF-7, the
hormone responsiveness is mediated by estrogen re-
ceptors (ERs) [1]. Activation of ER stimulates cyclin-
dependent kinases (CDKs) to induce proliferation of
MCF-7 cells. On the other hand, increased expres-
sion of cyclin kinase inhibitor p21 blocks CDK ac-
tivity necessary for retinoblastoma protein (pRb)
phosphorylation [2]. These results indicate that a
concerted e¡ect of di¡erent cell cycle proteins regu-
lates cell cycle progression.
Bone morphogenetic proteins (BMPs), BMP 1^9,
constitute a group of growth factors that are in-
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volved in ectopic bone formation [3]. They are pro-
duced as pro-mature forms, which are processed to
active dimers of the mature region in a manner sim-
ilar to the transforming growth factor L (TGFL) [4].
Due to this similarity, BMPs are categorized as mem-
bers of the TGFL super family. In addition to other
functions during embryonic development and limb
formation, BMPs regulate chondrogenesis and osteo-
genesis [5^7]. Though BMPs have been detected in
osteosarcomas and soft tissue carcinomas, the role of
BMPs in breast cancer is still unclear. Like TGFL
receptors, multiple BMP receptors have recently
been identi¢ed. They form two closely related groups
known as type I and type II receptors, which contain
multiple members. Both the receptor types have ser-
ine/threonine kinase activity in their cytoplasmic do-
mains [8,9]. Three downstream target molecules for
BMP-2 have recently been identi¢ed. These targets
are Smad 1, Smad 5 and Smad 8. BMP-2 stimulates
association of Smad 1 with the BMP receptor fol-
lowed by phosphorylation of the Smad 1 C-terminus
by the type I receptor [10,11]. Receptor-phosphory-
lated Smad 1 undergoes heterodimerization with the
tumor suppressor protein Smad 4. This heterodimer
then translocates to the nucleus and participates in
transcription of genes [10,12].
Recently, Nakaoka et al. demonstrated that BMP-
2 inhibits smooth muscle cell proliferation [13].
BMP-2 blocks serum and androgen-induced growth
of human prostate cancer cells in culture [14]. We
have recently shown that BMP-2 at a moderate
dose blocked PDGF and EGF-induced DNA synthe-
sis in primary glomerular mesangial cells without any
e¡ect on matrix gene expression [15,16]. Also a high
dose of recombinant BMP-2 has recently been shown
to inhibit soft agar growth of a variety of tumor
samples including breast tumor [17]. However, the
mechanism of BMP-2-mediated inhibition of tumor
cell growth is not known. In this report, we demon-
strate the inhibitory e¡ect of BMP-2 on estradiol-
induced MCF-7 human breast cancer cell prolifera-
tion in culture. BMP-2 increases the levels of cyclin
kinase inhibitor p21 without any e¡ect on estradiol-
induced cyclin D1 expression. We also show that
BMP-2 inhibits estradiol-induced cyclin D1-associ-
ated kinase and CDK2 activity with concomitant
reduction of pRb phosphorylation. This is the ¢rst
elucidation of the signaling mechanisms, involved in
BMP-2-mediated inhibition of estradiol-induced
breast cancer cell growth.
2. Materials and methods
Tissue culture materials were purchased from Gib-
co. Estradiol, phenyl methyl sulphonyl £uoride
(PMSF), soybean inhibitor, leupeptin, myelin basic
protein, propidium iodide and RNase A were ob-
tained from Sigma. Histone H1 was purchased
from Boehringer Mannheim. GST-pRb was obtained
from Santa Cruz. Micro BCA reagent and enhanced
chemiluminescence (ECL) kit were purchased from
Pierce. Protein A-Sepharose CL 4B was purchased
from Pharmacia. All antibodies were obtained from
Santa Cruz. Recombinant BMP-2 was obtained from
Genetics Institute.
MCF-7 breast cancer cells were obtained from Dr.
Robert Klebe (Department of Cellular and Structur-
al Biology, University of Texas Health Science Cen-
ter at San Antonio) and were routinely maintained in
DMEM^F12 medium containing 10% new born calf
serum. These MCF-7 cells are highly responsive to
estradiol and tamoxifen. For experiments designed to
test the mitogenic e¡ect of estradiol, cells were grown
in complete medium for 48 h to reach subcon£uency
and then placed in phenol red-free and serum-free
DMEM for 48 h before addition of estradiol. Treat-
ment with serum-free medium slows the growth of
cells because they tend to arrest at G0/G1 phase. For
cell cycle analysis near con£uent cells were used for
serum-deprivation to arrest in G0/G1 phase before
addition of estradiol to release them.
2.1. Flow cytometric analysis
MCF-7 cells were trypsinized and washed with
phosphate-bu¡ered saline (PBS). The cells were ¢xed
in 70% ethanol for 30 min at 320‡C, centrifuged at
1500Ug for 4 min, washed with PBS containing 1%
bovine serum albumin (BSA) and resuspended in 150
Wl PBS. For nuclear staining with propidium iodide,
the cells were treated with 50 Wl of 1 mg/ml RNase A
(Sigma) followed by 100 Wl of 100 Wg/ml propidium
iodide. The cells were incubated at 4‡C for 18^24 h
before they were analyzed by £ow cytometry on
FACStar Plus (Becton Dickinson Immunocytometry
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Systems, San Jose, CA). Cells were illuminated with
200 mW of light at 488 nm produced by an argon-
ion laser and the £uorescence was read using a 630/
22 nm band-pass ¢lter. Data were analyzed for
20 000 viable cells as determined by forward and
right angle light scatter and were stored as frequency
histograms and subsequently analyzed by MODFIT
software (Verity, Topsham, ME).
2.2. MTT (3-(4,5-dimethylthiazol-2,5-diphenyl
tetrazolium bromide) assay for cell proliferation
Proliferation of MCF-7 cells in response to estra-
diol was determined using the MTT assay as de-
scribed elsewhere [18]. In brief, 50 Wl of 5 mg/ml
MTT was added to the culture medium of growing
cells (1 ml medium/well) and incubated for 4 h at
37‡C in a humidi¢ed atmosphere with 5% CO2.
The medium was removed and 200 Wl of DMSO
was added to each well. The absorbance of the dis-
solved dye was measured at 540 nm.
2.3. Immunoprecipitation and immunoblotting
Immunoprecipitation was carried out according to
methods described elsewhere, with minor modi¢ca-
tions [16,19]. In brief, cells were lysed in immunopre-
cipitation bu¡er (50 mM Tris^HCl pH 7.5, 5 mM
EDTA, 10 mM EGTA, 50 mM NaF, 20 mM L-glyc-
erophosphate, 50 mM NaCl, 0.1% Nonidet P-40, 50
Wg/ml PMSF, 10 Wg/ml soybean trypsin inhibitor,
2 Wg/ml leupeptin, 1 Wg/ml aprotinin) and cleared of
cell debris by centrifugation at 4‡C. Protein estima-
tion was done in supernatant by a micro BCA assay.
200 Wg protein was routinely precleared by incubat-
ing with 20 Wl of swelled protein A-Sepharose beads
for 1 h in the cold. The cleared supernatant was
immunoprecipitated at 4‡C for 18^24 h using 1 Wg
of antibody followed by addition of 20 Wl swelled
protein A-Sepharose beads for 1 h. The protein A-
Sepharose beads containing the antigen^antibody
complex were then gently washed three times with
immunoprecipitation bu¡er before eluting the bound
proteins in the sodium dodecyl sulfate (SDS)^poly-
acrylamide gel loading bu¡er.
Immunoblotting was performed essentially as pre-
viously described [20]. Brie£y, the cleared cell lysates
or immunoprecipitates were separated in SDS^poly-
acrylamide gels (12% or 7.5% depending on the pro-
tein sizes). The proteins were electrophoretically
transferred onto Nytran membrane. Following the
transfer, the proteins were incubated with blocking
solution (50 mM Tris^HCl pH 7.4^150 mM NaCl^
0.2% Tween 20 (TBST) containing 5% non-fat dry
milk) for 1 h at room temperature, followed by over-
night incubation in primary antibody solution pre-
pared in TBST containing 1% BSA. The membrane
was subsequently washed ¢ve times in TBST for
5 min each, before the horseradish peroxidase-con-
jugated secondary antibody was added in TBST for
1 h at room temperature. The membrane was ¢nally
washed in TBST, ¢ve times for 5 min each and the
antigen^antibody complex was detected using an
ECL kit (Pierce) as per manufacturer’s recommenda-
tions.
2.4. Cyclin D1-associated kinase and CDK2 assay
The assay was performed using the method of
Gong et al. [21]. Brie£y, cleared cell lysate was im-
munoprecipitated using antibody against cyclin D1
or CDK2 as described above. The immunecomplex
beads were resuspended in kinase bu¡er (20 mM
Tris^HCl pH 7.5 and 4 mM MgCl2). To measure
the cyclin D1-associated kinase activity, a fragment
of pRb, that contains the in vivo phosphorylation
sites, was used. For CDK2 activity, calf thymus his-
tone H1 was used as a substrate. The reaction was
carried out in the presence of 25 WM ‘cold’ ATP and
10 WCi [Q-32P]ATP for 30 min at 37‡C. The
phosphorylated proteins were analyzed by SDS^
polyacrylamide gel electrophoresis followed by auto-
radiography. Phosphorylation was quantitated using
a densitometric scan of the phosphorylated bands in
autoradiogram.
3. Results
3.1. Growth inhibition of MCF-7 cells by BMP-2
Estradiol is a potent mitogen for ER positive hu-
man MCF-7 breast carcinoma cells [22]. To establish
the optimal conditions to assess the e¡ect of BMP-2
on MCF-7 cell proliferation, MCF-7 cells were
treated with 1 nM 17-L-estradiol for 24 and 48 h,
BBAMCR 14646 5-7-00
N. Ghosh-Choudhury et al. / Biochimica et Biophysica Acta 1497 (2000) 186^196188
respectively, and the cell number was counted. As
expected, estradiol increased the cell number at
each time point (Fig. 1A). To examine the e¡ect of
estradiol on cell cycle progression, MCF-7 cells were
subjected to £ow cytometry. At 24 and 48 h, a sig-
ni¢cantly higher percentage of cells were in S-phase
in the presence of estradiol, as compared to unstim-
ulated control cells (Fig. 1B). At 48 h, 10% of cells
entered the S-phase even in the absence of estradiol.
This may be due to incomplete quiescence of MCF-7
breast tumor cells. An alternative possibility may be
accumulation of mitogens in the culture medium dur-
ing 48 h of incubation in the serum-deprived me-
dium.
To determine the e¡ect of BMP-2 on cell cycle
progression of MCF-7 cells stimulated by estradiol,
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cells were incubated with estradiol for 24 and 48 h,
either in presence or absence of BMP-2. BMP-2 in-
hibited estradiol-induced S-phase progression of
these cells. Quantitation of these results shows that
only 62% and 45% of estradiol-treated MCF-7 cells
entered S-phase at 24 and 48 h, respectively, in the
presence of BMP-2 (Fig. 1C, left and right panels).
BMP-2 alone also inhibited S-phase entry of control
cells, by 41% and 43% at 24 and 48 h, respectively.
To determine if the e¡ect of BMP-2 on estradiol-
induced cell cycle progression correlated with cell
growth, MTT assays were performed. Fig. 1D shows
that BMP-2 signi¢cantly inhibited estradiol-stimu-
lated as well as basal MCF-7 cell proliferation. A
photomicrograph of MCF-7 cells in the absence
and presence of BMP-2 is shown in Fig. 2. As evi-
dent, treatment of these cells for 48 h with BMP-2
does not have any toxic e¡ect. Taken together, these
results indicate that BMP-2 inhibits estradiol-induced
cell growth by preventing the entry of MCF-7 cells
into S-phase.
3.2. BMP-2 stimulates expression of cyclin kinase
inhibitor, p21, in estradiol-treated MCF-7 cells
Progression of the cell cycle is regulated by a series
of CDKs [23]. These serine/threonine kinases are
positively regulated by cyclins [24,25]. One of the
G1 phase cyclins, cyclin D1, is overexpressed in
more than 50% of human breast adenocarcinomas
[26^28]. We studied the e¡ect of estradiol on cyclin
D1 expression. In accordance with the previous re-
port [29], estradiol treatment of MCF-7 cells in-
creased the level of cyclin D1 (Fig. 3A, compare
lane 2 with lane 1). However, pretreatment of
MCF-7 cells with BMP-2 had no signi¢cant e¡ect
on estradiol-induced expression of cyclin D1 (Fig.
3A, compare lane 4 with lane 2). These data indicate
that the e¡ect of BMP-2 on estradiol-induced MCF-
7 cell proliferation is not caused by the modulation
of cyclin D1 levels during cell cycle progression.
CDK activity is also regulated by cyclin kinase
inhibitors [25]. One such protein, p21, is a universal
Fig. 2. Photomicrograph of MCF-7 cells in the presence and absence of BMP-2. Serum-deprived MCF-7 cells were incubated with
BMP-2 for 48 h before taking the photograph. The phase contrast photomicrograph is shown.
Fig. 1. E¡ect of estradiol and BMP-2 on MCF-7 cell proliferation. (A) Con£uent layers of MCF-7 cells in 35 mm tissue culture dishes
were serum-starved for 48 h and incubated with 1 nM estradiol for 24 and 48 h. Cells in each dish were counted. Increase in cell
number was 1.6- and 1.8-fold, respectively, at 24 and 48 h. (B) Flow cytometric analysis of estradiol-induced MCF-7 cell proliferation.
Serum-deprived MCF-7 cells were grown in the presence or absence of 1 nM estradiol for 24 and 48 h. Cells were then trypsinized
and analyzed by £ow cytometry as described in Section 2. The percentage of cells in S-phase was plotted. The percentage of cells in
S-phase was increased by 6.5- and 3.7-fold at 24 and 48 h, respectively. Means of triplicate determinations are shown in A and B. (C)
Quantitation of £ow cytometric analysis of cells treated with BMP-2 and estradiol. MCF-7 cells were treated with 100 ng/ml BMP-2
and 1 nM estradiol for 24 h (left panel) and 48 h (right panel) before subjecting them to £ow cytometric analysis. The percentage of
cells in S-phase was plotted for each condition. (D) E¡ect of BMP-2 on estradiol-induced MCF-7 cell proliferation. 48 h serum-de-
prived MCF-7 cells were treated with 100 ng/ml BMP-2 and 1 nM estradiol. MTT assay was performed as an index of cell prolifera-
tion as described in Section 2. Results are means þ S.E.M. of three independent experiments. *P6 0.05 vs. untreated cells. ++P6 0.05
vs. untreated control. @P6 0.05 vs. estradiol-treated cells.
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inhibitor of CDKs, that interacts with multiple cy-
clin^CDK complexes. It thereby inhibits their kinase
activity, which drives the cells through the cell cycle
[2,30,31]. To understand the mechanism of BMP-2
inhibition of cell cycle progression, we studied its
e¡ect on p21 expression. MCF-7 cells were incubated
with BMP-2 and estradiol for 6 and 48 h. At both
time points, estradiol did not have any a¡ect on p21
protein expression as determined by immunoblot
analysis (Fig. 3B,C, compare lanes 2 with lanes 1
in both panels). In contrast, treatment of MCF-7
cells with BMP-2 alone signi¢cantly increased the
level of p21 protein expression (Fig. 3B,C, compare
lanes 3 with lanes 1). In the cells co-treated with
BMP-2 and estradiol (lane 4), the level of p21 ex-
pression remained increased as compared to un-
treated and estradiol-treated cells. These data indi-
cate that the inhibitory e¡ect of BMP-2 on MCF-7
cell proliferation may partly be due to its e¡ect on
increased expression of p21.
3.3. BMP-2 inhibits cyclin D1-associated kinase
activity via p21
For p21 to exert its inhibitory e¡ect on cell cycle
progression, it must associate with one of the cyclin^
CDK complexes [24,25]. Since estradiol-induced in-
crease in cyclin D1 levels resulted in cell progression,
while BMP-2-induced increase in p21 levels caused
G1 arrest, we analyzed the association of p21 with
cyclin D1 under similar conditions. Lysates of serum-
deprived MCF-7 cells treated with estradiol in the
presence and absence of BMP-2 were immunopreci-
pitated with the antibody to p21, followed by immu-
noblotting with a cyclin D1 antibody. As shown in
Fig. 4A, estradiol alone has no e¡ect on association
of cyclin D1 with p21. In contrast, p21 was found to
be associated with cyclin D1 in cells treated with
BMP-2 alone or in combination with estradiol (Fig.
4A, lanes 3 and 4). These data indicate that BMP-2
treatment causes an increased association of p21 with
Fig. 3. (A) E¡ect of BMP-2 on estradiol-induced expression of cyclin D1 and p21. MCF-7 cells serum-deprived for 48 h were incu-
bated with 1 nM estradiol in the presence and absence of 100 ng/ml BMP-2 for subsequent 48 h. Cleared cell lysates were analyzed
by immunoblotting with cyclin D1. (B and C) E¡ect of BMP-2 on p21 expression. Serum-deprived MCF-7 cells were incubated with
estradiol in the presence and absence of 100 ng/ml BMP-2 for 6 h (B) and 48 h (C), respectively. The lysates were immunoblotted
with p21 antibody and the signal was developed by ECL. Lower panels show immunoblotting of the same lysates with anti-actin anti-
body to demonstrate equal loading of proteins in each lane.
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cyclin D1 in MCF-7 cells which may result in the
inhibition of cyclin D1-dependent kinase activity.
More recently, a role for p21 has been described as
the assembly factor for cyclin D and CDK4/6 [32,33].
Fig. 5. (A) E¡ect of BMP-2 on association of p21 with cyclin E. Cleared cell lysates from MCF-7 cells, treated as described in Fig. 4,
were immunoprecipitated (I.P.) with anti-cyclin E. The immunoprecipitated proteins were eluted from the immunebeads, separated on
a 15% SDS^polyacrylamide gel and were immunoblotted (I.B.) with anti-p21 antibody. E¡ect of BMP-2 on estradiol-induced CDK2
activity. (B) The cleared cell lysates from MCF-7 cells treated as described in Fig. 4 were immunoprecipitated with an anti-CDK2
antibody. The washed immunebeads were used in an in vitro immunecomplex kinase assay with histone H1 as substrate in the pres-
ence of [Q-32P]ATP. The labeled proteins were separated by SDS gel electrophoresis and visualized by autoradiography. The lower
panel shows immunoblotting of the same lysates with anti-actin antibody. (C) Quantitation of histone H1 phosphorylation. The radio-
activity incorporated into histone H1 in (A) was measured by a densitometric scan as described in Section 2 and plotted as histo-
gram.
Fig. 4. (A) E¡ect of BMP-2 on association of p21 with cyclin
D1. Cleared cell lysates from MCF-7 cells, treated as described
in Fig. 3B,C, were immunoprecipitated (I.P.) with either anti-
p21 or control IgG. The immunoprecipitated proteins were
eluted from the immunebeads, separated on a 12% SDS^polyac-
rylamide gel and were immunoblotted (I.B.) with anti-cyclin D1
antibody. Lanes 1^4 represent p21 immunoprecipitates. Lane 5
shows IgG immunoprecipitates. (B) E¡ect of BMP-2 on estra-
diol-induced cyclin D1-associated kinase activity. Serum-de-
prived MCF-7 cells were incubated with estradiol in the pres-
ence of BMP-2. The lysates were immunoprecipitated with
cyclin D1 antibody. The immunoprecipitates were assayed for
kinase activity in the presence of [Q-32P]ATP using pRb as sub-
strate. The labeled protein was separated by SDS gel electro-
phoresis and visualized by autoradiography. The lower panel
shows an immunoblot of same samples with actin antibody.
C
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Another role of p21 in cell cycle is its inhibitory
e¡ect on CDK activity. Increased expression of p21
has been shown to inhibit both cyclin D1 and cyclin
E-associated kinases [2]. To test this, lysates of
MCF-7 cells treated with BMP-2 and estradiol were
immunoprecipitated with cyclin D1 antibody. The
immunoprecipitates were assayed for D1-associated
kinase activity using pRb as in vitro substrate. As
shown in Fig. 4B, BMP-2 inhibited estradiol-induced
cyclin D1-associated kinase activity (compare lane 2
with lane 1). These data indicate that the inhibitory
e¡ect of BMP-2 may involve reduced pRb phosphor-
ylation by cyclin D1-associated kinase (see below).
3.4. BMP-2 inhibits estradiol-induced CDK2 kinase
activity and pRb phosphorylation
In the late G1 phase of cell cycle progression, E-
type cyclin regulates CDK activity which is necessary
for cells to enter and proceed through the S-phase
[34]. p21 has been shown to regulate cyclin E via
physical association. Since the p21 level was in-
creased by BMP-2 (Fig. 3B,C), we tested if recombi-
nant BMP-2 regulates p21 association with cyclin E.
Cyclin E immunoprecipitates from lysates of estra-
diol or BMP-2 plus estradiol-treated MCF-7 cells
were immunoblotted with p21 antibody. The results
show that BMP-2 stimulated increased association of
p21 with cyclin E in the presence and absence of
estradiol as compared to estradiol alone (Fig. 5A,
compare lanes 3 and 4 with lane 2). During late
G1 and S-phase, cyclin E regulates CDK2 activity.
To understand the mechanism of regulation of
CDK2 in MCF-7 breast cancer cells, we analyzed
the kinase activity associated with CDK2 in cells
treated with estradiol in the presence or absence of
BMP-2. Cell lysates were immunoprecipitated with a
CDK2 antibody. The immunebeads were then used
in an in vitro immunecomplex kinase assay with his-
tone H1 as substrate in the presence of [Q-32P]ATP.
The data showed increased phosphorylation of his-
tone H1 by CDK2 in cells treated with estradiol (Fig.
5B, compare lane 2 with 1). Estradiol-induced CDK2
activity was signi¢cantly inhibited by BMP-2 (Fig.
5B, compare lane 4 with lane 2). Quantitation of
histone H1 phosphorylation showed 11-fold increase
in CDK2 activity in the presence of estradiol (Fig.
5C), and BMP-2 inhibited 70% of estradiol-induced
CDK2 activity (Fig. 5C). BMP-2 also partially inhib-
ited the basal activity of CDK2 in MCF-7 cells.
These data indicate that BMP-2-mediated inhibition
of estradiol-induced MCF-7 proliferation may in
part be due to its inhibitory e¡ect on CDK2 activity.
One of the targets of CDKs during cell cycle pro-
gression is pRb [24,35]. Hypophosphorylated pRb is
active and inhibits cell cycle progression. Prolifera-
tive signals integrate into the nucleus to induce
CDK-dependent phosphorylation of pRb rendering
pRb inactive and resulting in DNA synthesis [35].
We showed in Fig. 4B that in in vitro kinase assay,
pRb phosphorylation is reduced by BMP-2. To study
the e¡ect of BMP-2 on estradiol-induced pRb phos-
phorylation in MCF-7 cells, we analyzed lysates of
MCF-7 cells by phosphorylation-dependent mobility
shift assay. The degree of pRb phosphorylation is
determined by its electrophoretic mobility, with hy-
perphosphorylated pRb forms migrating slower than
the hypophosphorylated form in SDS gel. Lysates
from MCF-7 cells, treated with estradiol or BMP-2
alone or with estradiol in the presence of BMP-2,
were immunoblotted with an anti-pRb antibody. As
shown in Fig. 6, estradiol caused hyperphosphoryla-
tion of pRb as indicated by the slower migration of
this protein (lane 1, indicated by ¢lled circle). Treat-
ment of MCF-7 cells with BMP-2 alone resulted in
the partial phosphorylation of pRb (lane 2, indicated
Fig. 6. E¡ect of BMP-2 on estradiol-induced pRb phosphory-
lation. The cleared cell lysates of MCF-7 cells, treated with es-
tradiol in the presence and absence of BMP-2, were immuno-
blotted with an anti-pRb antibody. The migration of molecular
weight markers (in kDa) is shown in the left margin. The ¢lled
circle shows hyperphosphorylated pRb in the highest phosphor-
ylated form. The open circle shows pRb in intermediate
phosphorylated form and the ¢lled triangle shows pRb in hypo-
phosphorylated form.
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by open circle). In contrast, BMP-2 signi¢cantly in-
hibited hyperphosphorylation of pRb induced by es-
tradiol and only hypophosphorylated pRb was the
predominant form detected (Fig. 6, lane 3, indicated
by ¢lled triangle). These data indicate that the ob-
served growth inhibitory e¡ect of BMP-2 in estra-
diol-induced MCF-7 breast cancer cell proliferation
could be caused by decreased CDK-dependent pRb
phosphorylation.
4. Discussion
Our study demonstrates an inhibitory e¡ect of
BMP-2 on estradiol-induced MCF-7 breast cancer
cell proliferation. BMP-2 stimulates increased expres-
sion of p21 cyclin kinase inhibitor. Consistent with
this idea is our observation showing inhibition of
estradiol-induced cyclin D1-associated kinase and
CDK2 activity in response to BMP-2. Finally, we
provide the ¢rst evidence that BMP-2 maintains the
pRb tumor suppressor protein in a partially
phosphorylated form.
Binding of estrogen to its receptor regulates a co-
hort of responsive genes that appears to regulate cell
cycle progression. CDK4 and CDK6 form complexes
with D-type cyclins during mid and late phases of
G1, while CDK2 binds to cyclin E and D during
late G1 [36^38]. One link between proliferative sig-
nals and cell cycle progression is provided by the
induction of the secondary response genes, such as
cyclin D1, following mitogenic stimulation [36]. In
breast cancer, chromosome 11q13, which contains
the cyclin D1 gene, has been shown to be ampli¢ed
preferentially in ER positive tumors [39,40]. It has
also been suggested that overexpression of cyclin
D1 in MCF-7 cells causes them to proliferate in
growth factor-deprived conditions [41]. In simvasta-
tin or lovastatin-arrested MCF-7 human breast can-
cer cells, estrogen stimulates cell cycle entry by in-
creasing cyclin D1 expression [42]. This e¡ect of
estrogen was due to transcriptional activation of
the cyclin D1 gene by an estrogen-regulated response
region present between the 3944 bp of upstream
sequences and the transcription start site of the cyclin
D1 gene [42]. Cyclins, in association with CDKs and
cyclin kinase inhibitors, control cell cycle progression
through di¡erent phases of transitions and check-
points. One of the cyclin kinase inhibitors, p21, has
been shown to stimulate withdrawal from the cell
cycle coupled to terminal di¡erentiation [43]. Immu-
nohistochemical analysis of breast carcinomas has
shown that increased expression of p21 was associ-
ated with relapse-free survival [44]. p21 inhibits all
the CDKs associated with cyclins A, D1 and E that
are required for G1/S progression [31,45]. In addition
to CDK inhibition, and thereby blocking cells from
entering S-phase, p21 inhibits the DNA replication
directly by binding to PCNA [46]. In the present
study, we show that estradiol-induced S-phase entry
of MCF-7 breast carcinoma cells is inhibited by the
growth and di¡erentiation factor BMP-2 (Fig. 1).
Furthermore, our results demonstrate that BMP-2
causes increase in the levels of p21 protein as early
as 6 h which sustains until 48 h (Fig. 3B,C). These
data indicate that our observation of BMP-2-induced
reduction in S-phase entry (Fig. 1C) and reduced
proliferation (Fig. 1D) may be due to the increased
expression of p21 protein (Fig. 3B,C). One of the
mechanisms by which p21 blocks cells from entering
S-phase is via interaction with cyclin D1 during G1
phase of the cell cycle, subsequently resulting in in-
hibition of CDK4 activity [2]. In the present study,
we demonstrate association of p21 with cyclin D1 in
the presence of BMP-2 (Fig. 4A). This may be the
cause of reduced cyclin D1-associated kinase activity
(Fig. 4B).
In addition to activation of cyclin D1/CDK4 dur-
ing G1 phase, activation of cyclin E/CDK2 in late
G1 is required for cells to progress through the cell
cycle [38,47]. p21 inhibits both cyclin D1/CDK4 ac-
tivity and cyclin E/CDK2 activity [2,30,48]. Treat-
ment of MCF-7 breast cancer cells with estradiol
stimulates cyclin D1-associated kinase (Fig. 4B) and
CDK2 activity (Fig. 5B), which con¢rms the pre-
vious ¢nding [47]. Pretreatment of cells with BMP-
2, however, signi¢cantly blocked the estrogen-in-
duced increase in both these kinase activities (Figs.
4B and 5B). Furthermore, BMP-2 increased the as-
sociation of p21 with cyclin E (Fig. 5A). Our data for
the ¢rst time demonstrate that BMP-2 targets the cell
machinery at the level of CDKs. Thus one of the
mechanisms by which BMP-2 inhibits MCF-7 cell
proliferation is by inhibiting CDKs that are known
to be activated in mid to late G1 and S-phases of cell
cycle.
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One of the targets of G1 CDKs is the tumor sup-
pressor protein pRb [35]. This notion is established
from various in vitro and in vivo studies. Cyclin D1/
CDK4 complex can phosphorylate pRb in vitro [49].
The physiologic regulators that intercept CDK4/6
activity also block pRb phosphorylation. Similarly,
overexpression of cyclin E in human osteosarcoma
cells increases pRb phosphorylation [50]. pRb is
also hyperphosphorylated in various breast cancer
cells and tissues by cyclin E/CDK2 activity [51]. In
tamoxifen-arrested MCF-7 cells, estradiol stimulates
cyclin E/CDK2-dependent pRb phosphorylation [47].
We have also shown that treatment of serum-de-
prived MCF-7 cells with estradiol increased the level
of hyperphosphorylated inactive pRb and that pres-
ence of BMP-2 during estradiol treatment caused
reduction in the degree of pRb phosphorylation
(Fig. 6). These observations describe one of the ¢rst
mechanisms by which BMP-2 may inhibit MCF-7
breast cancer cell growth in culture.
In summary, we have demonstrated that BMP-2
inhibits estradiol-induced proliferation of human
breast cancer cells. This e¡ect of BMP-2 appears to
be mediated by inhibition of positive cell cycle regu-
latory proteins. Hyperproliferation of estrogen-re-
sponsive breast cancer cells is one of the major
causes of tumor formation in early stages of breast
cancer. Agents such as BMP-2 that inhibit estradiol-
induced breast cancer cell proliferation may prove to
be important therapeutic tools once their mecha-
nisms of action are more thoroughly characterized.
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